ClinicalTrials.gg
CompletedNCT03284398Updated Jan 29, 2021Results posted

Three-Chamber Bags Retrospective Study in Spain

An observational study in Parenteral Nutrition and Blood Stream Infection, sponsored by Fresenius Kabi. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by Fresenius Kabi · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
3,723
Ages
18 Years and older
Sex
All
01

Study summary

The primary study objective is to assess the rates of blood stream infection (BSI) from the use of Three-Chamber Bags (e.g., SmofKabiven®, Kabiven®, others) compared to Hospital Compounded Bags (HCBs) in patients requiring parenteral nutrition in Spanish hospitals.

Read the detailed description

This is a retrospective observational database study of patients receiving parenteral nutrition (PN) for at least 3 consecutive days with hospital admission date between January 1, 2013, and December 31, 2015 (study period).

The study will use an as treated approach, where patients will be followed from the index date (hospital admission day of the hospitalization during which PN is administered) up to patient discharge or death (observation period).

The study will be conducted using an initial EMR (Electronic Medical Record) data retrieval process, followed by manual data retrieval (chart review) that will complement data obtained from EMR. Data collection for manual data retrieval will be conducted through an eCRF.

The documentation of patient data will comprise two sequential steps. The initial step will include data of 30% of patients and then an interim analysis (IA) will be conducted. If IA shows positive results, data for the remaining 70% of patients (step II) will be gathered.

The study will be conducted in 10-14 sites in Spain.

Data analysis: Baseline demographics, co-morbidities, and hospitalization characteristics will be reported descriptively by means of mean with standard deviations and medians with ranges for continuous variables and by counts and percentages for categorical variables. Incidence rates for BSI will be reported by treatment group.

02

Conditions studied

  • Parenteral Nutrition
  • Blood Stream Infection

Keywords

  • parenteral nutrition
  • ICU
  • 3-chamber bags
  • ICD-9-CM
  • BSI
  • Medical records system
  • computerized
03

In context

Lead sponsor

Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Population will include adult hospitalized patients receiving PN, treated on any ward and by any medical discipline within the hospital (e.g., intensive care unit, normal wards; surgery, non-surgery) during the study period. For every patient, one hospitalization episode will be documented.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult hospital inpatients ≥ 18 years
  2. Treatment with PN for at least 3 consecutive days
  3. PN containing all three major macronutrients, delivered from 3CB or HCB
  4. Patients with hospital admission between January 1, 2013, and December 31, 2015 (study period)

Exclusion criteria

Exclusion Criteria:

  1. Bloodstream infection before or at the same day of first PN administration
  2. due to concomitant therapy (e.g., immunosuppressive therapy due to transplantation, concomitant oral or intravenous administration of ) or disease (e.g., , leukaemia)
  3. Permanent vascular access (port, shunts for dialysis)
  4. Femoral venous placement of central venous line used for PN
  5. Burns, extensive skin injuries (e.g., Lyell´s disease)
  6. Chemo-/radiotherapy for up to 3 months before hospital admission
  7. Change of PN bag type during observation period, e.g., from HCBs to 3CBs or vice-versa
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
3,723 participants (actual)
Patient registry
No

Groups and cohorts

  • Parenteral nutrition bag type

    Groups with different parenteral nutrition bags (3CBs or HCBs)

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB)

    Confirmation of BSI required fulfillment of all of the following criteria: * International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code for sepsis (038.x), septicemia (995.91), severe sepsis (995.92), septic shock (785.52), bacteremia (790.7), unspecified infection due to central venous catheter (999.31), or BSI due to central venous catheter (999.32) * Positive blood culture collected during PN administration * Concomitant antimicrobial therapy

    Time frame: Entire study period, from January 1, 2013 and December 31, 2015

Secondary outcomes

  1. Sepsis During PN

    Percentage of patients presenting at least one episode of Sepsis during treatment with PN for each group (3CB vs HCB)

    Time frame: From date of admission to date of discharge

  2. Treatment With Antimicrobials During PN

    Percentage of patients receiving antimicrobial agents during treatment with PN for each group (3CB vs HCB)

    Time frame: Any day during PN treatment

  3. Use of Vasopressor Treatment

    Percentages of patients requiring vasopressor support during PN treatment

    Time frame: Patients requiring vasopressor support at any time during treatment with PN

  4. Use of Mechanical Ventilation

    Percentage of patients requiring mechanical ventilation during PN treatment for each group (3CB vs HCB)

    Time frame: Patients requiring mechanical ventilation at any time during PN treatment

  5. Renal Replacement Therapy

    Percentage of patients requiring Renal Replacement Therapy during PN treatment for each group (3CB vs HCB)

    Time frame: Patients requiring renal replacement therapy for at least one day during PN treatment

  6. Newly-occurred Abnormal Laboratory Findings During PN

    Percentage of patients presenting newly-occurred abnormal laboratory results during PN for each group (3CB vs HCB)

    Time frame: During PN treatment inclusive day 1

  7. Organ Failure

    Percentage of patients presenting at least one organ failure during treatment with PN for each group (3CB vs HCB)

    Time frame: Any time during PN treatment

  8. Hospital Length of Stay (LOS)

    Hospital length of stay in days for patients for each group (3CB vs HCB)

    Time frame: Duration in days from admission to death or discharge for each treatment arm

  9. Length of Stay in the ICU

    Total number of days in the ICU for each group (3CB vs HCB)

    Time frame: All patients admitted in the ICU at any time during PN treatment

07

Results

Posted Jan 8, 2021

Participant flow

Retrospective cohort study. Data collection from medical records

Participant flow — Overall Study
MilestoneThree-chambered Bag (3CB)Hospital-Compounded Bag (HCB)
Started2753970
Completed2753970
Not completed00

Outcome measures

PrimaryPercentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB)

Confirmation of BSI required fulfillment of all of the following criteria: * International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code for sepsis (038.x), septicemia (995.91), severe sepsis (995.92), septic shock (785.52), bacteremia (790.7), unspecified infection due to central venous catheter (999.31), or BSI due to central venous catheter (999.32) * Positive blood culture collected during PN administration * Concomitant antimicrobial therapy

Time frame:
Entire study period, from January 1, 2013 and December 31, 2015
Reported as:
Count of participants · Participants
Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB)
ParticipantsThree-Chambered BagHospital-compounded Bag
Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB)127106
SecondarySepsis During PN

Percentage of patients presenting at least one episode of Sepsis during treatment with PN for each group (3CB vs HCB)

Time frame:
From date of admission to date of discharge
Reported as:
Count of participants · Participants
Sepsis During PN
ParticipantsThree-Chambered Bag (3CB)Hospital-Compounded Bag (HCB)
Sepsis During PN431228
SecondaryTreatment With Antimicrobials During PN

Percentage of patients receiving antimicrobial agents during treatment with PN for each group (3CB vs HCB)

Time frame:
Any day during PN treatment
Reported as:
Count of participants · Participants
Treatment With Antimicrobials During PN
ParticipantsThree-chambered Bag (3CB)Hospital-Compounded Bag (HCB)
Treatment With Antimicrobials During PN831370
SecondaryUse of Vasopressor Treatment

Percentages of patients requiring vasopressor support during PN treatment

Time frame:
Patients requiring vasopressor support at any time during treatment with PN
Reported as:
Count of participants · Participants
Use of Vasopressor Treatment
ParticipantsThree-Chambered Bag (3CB)Hospital-compounded Bag (HCB)
Use of Vasopressor Treatment410291
SecondaryUse of Mechanical Ventilation

Percentage of patients requiring mechanical ventilation during PN treatment for each group (3CB vs HCB)

Time frame:
Patients requiring mechanical ventilation at any time during PN treatment
Reported as:
Count of participants · Participants
Use of Mechanical Ventilation
ParticipantsThree-Chambered Bag (3CB)Hospital-compounded Bag (HCB)
Use of Mechanical Ventilation410299
SecondaryRenal Replacement Therapy

Percentage of patients requiring Renal Replacement Therapy during PN treatment for each group (3CB vs HCB)

Time frame:
Patients requiring renal replacement therapy for at least one day during PN treatment
Reported as:
Count of participants · Participants
Renal Replacement Therapy
ParticipantsThree-Chambered Bag (3CB)Hospital-compounded Bag (HCB)
Renal Replacement Therapy7889
SecondaryNewly-occurred Abnormal Laboratory Findings During PN

Percentage of patients presenting newly-occurred abnormal laboratory results during PN for each group (3CB vs HCB)

Time frame:
During PN treatment inclusive day 1
Reported as:
Count of participants · Participants
Newly-occurred Abnormal Laboratory Findings During PN
ParticipantsThree-Chambered Bag (3CB)Hospital-compounded Bag (HCB)
Metabolic impairment1193584
Any hepatic dysfunction1414651
Any abnormal electrolytes1444699
SecondaryOrgan Failure

Percentage of patients presenting at least one organ failure during treatment with PN for each group (3CB vs HCB)

Time frame:
Any time during PN treatment
Reported as:
Count of participants · Participants
Organ Failure
ParticipantsThree-Chambered Bag (3CB)Hospital-compounded Bag (HCB)
Any organ failure905562
Single organ failure593255
Multiple organ failure312307
SecondaryHospital Length of Stay (LOS)

Hospital length of stay in days for patients for each group (3CB vs HCB)

Time frame:
Duration in days from admission to death or discharge for each treatment arm
Reported as:
Number · Days
Hospital Length of Stay (LOS)
DaysThree-Chambered Bag (3CB)Hospital-compounded Bag (HCB)
Hospital Length of Stay (LOS)26,60130,384
SecondaryLength of Stay in the ICU

Total number of days in the ICU for each group (3CB vs HCB)

Time frame:
All patients admitted in the ICU at any time during PN treatment
Reported as:
Number · Days
Length of Stay in the ICU
DaysThree-Chambered Bag (3CB)Hospital-compounded Bag (HCB)
Length of Stay in the ICU3,0173,772

Adverse events

Collected over Retrospective, observational, non-interventional study. All-cause mortality, Serious and Other (Not Including Serious) Adverse Events were not monitored/assessed. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Three-Chambered Bag (3CB)———
Hospital-compounded Bag (HCB)———

Baseline characteristics

A total of 5389 patient records were screened for eligibility; of these, 3723 met the selection criteria, including 2753 patients who received 3CB and 970 patients who received MCB

Age, Continuous
Age, Continuous(years)Three-Chambered Bag (3CB)Hospital-compounded Bag (HCB)Total
Mean66.8 ± 15.266.5 ± 14.866.8 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)Three-Chambered Bag (3CB)Hospital-compounded Bag (HCB)Total
Female11443541498
Male16096162225
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Three-Chambered Bag (3CB)Hospital-compounded Bag (HCB)Total
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Three-Chambered Bag (3CB)Hospital-compounded Bag (HCB)Total
Spain27539703723
08

Study locations

2 sites
  • Hospital de Manacor
    Manacor, Islas Baleares 7500, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in May 2019, 17 months.

Results were first posted in Jan 2021, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2017
First posted
Sep 15, 2017
StartActual
Dec 14, 2017
Primary completionActual
May 31, 2019
CompletionActual
May 31, 2019
Results first posted
Jan 8, 2021
Last update
Jan 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03284398
Lead sponsor
Fresenius Kabi
Responsible party
Sponsor
First posted
Sep 15, 2017
Start date
Dec 14, 2017
Primary completion
May 31, 2019
Completion
May 31, 2019
Results posted
Jan 8, 2021
Last update
Jan 29, 2021

Study contacts

John F Stover
study chair · Fresenius Kabi Deutschland GmbH, Borkenberg 14, 61440 Oberursel, Germany
Juan Carlos M González
principal investigator · Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion